Hill-Rom (HRC) Given “Buy” Rating at Needham & Company LLC
Needham & Company LLC reaffirmed their buy rating on shares of Hill-Rom (NYSE:HRC) in a report released on Tuesday, MarketBeat reports. The firm currently has a $105.00 price target on the medical technology company’s stock, up from their prior price target of $90.00.
“HRC preannounced above-consensus F1Q18 revenue and EPS. Management also provided an update on tax reform and expects its tax rate to fall by ~500 bps to ~24%. We have raised our EPS estimates to reflect the positive preannouncement and tax rate guidance. HRC shares remain at a discount to peers (2018E P/E 18.3x which is a 22% discount to its small/mid-cap value peers’ median 2018E P/E of 23.5x) and we reiterate our Buy rating.”,” Needham & Company LLC’s analyst wrote.
A number of other research analysts have also recently commented on HRC. Zacks Investment Research upgraded shares of Hill-Rom from a sell rating to a hold rating in a research report on Monday, September 18th. KeyCorp reiterated a buy rating and set a $82.00 price target on shares of Hill-Rom in a research report on Tuesday, October 17th. ValuEngine cut shares of Hill-Rom from a buy rating to a hold rating in a research report on Saturday, November 4th. Stifel Nicolaus increased their price target on shares of Hill-Rom from $84.00 to $85.00 and gave the company a buy rating in a research report on Monday, November 6th. Finally, Barclays increased their price target on shares of Hill-Rom from $86.00 to $90.00 and gave the company an overweight rating in a research report on Monday, November 6th. Five equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. Hill-Rom presently has a consensus rating of Buy and a consensus target price of $95.38.
Hill-Rom (NYSE:HRC) last issued its quarterly earnings results on Friday, November 3rd. The medical technology company reported $1.32 EPS for the quarter, beating analysts’ consensus estimates of $1.27 by $0.05. Hill-Rom had a net margin of 4.87% and a return on equity of 20.27%. The business had revenue of $738.30 million for the quarter, compared to analysts’ expectations of $731.10 million. During the same period last year, the business earned $1.18 earnings per share. The business’s quarterly revenue was up 4.6% on a year-over-year basis. equities analysts anticipate that Hill-Rom will post 4.37 earnings per share for the current fiscal year.
The business also recently disclosed a quarterly dividend, which was paid on Friday, December 29th. Stockholders of record on Friday, December 15th were paid a dividend of $0.18 per share. This represents a $0.72 dividend on an annualized basis and a dividend yield of 0.81%. The ex-dividend date of this dividend was Thursday, December 14th. Hill-Rom’s dividend payout ratio (DPR) is presently 36.18%.
In other news, CEO John J. Greisch sold 100,000 shares of the stock in a transaction that occurred on Tuesday, December 12th. The stock was sold at an average price of $82.82, for a total transaction of $8,282,000.00. Following the completion of the sale, the chief executive officer now owns 230,851 shares of the company’s stock, valued at $19,119,079.82. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CEO John J. Greisch sold 125,241 shares of the stock in a transaction that occurred on Friday, December 15th. The shares were sold at an average price of $82.59, for a total value of $10,343,654.19. Following the sale, the chief executive officer now directly owns 280,851 shares of the company’s stock, valued at approximately $23,195,484.09. The disclosure for this sale can be found here. In the last three months, insiders have sold 226,241 shares of company stock valued at $18,708,644. Insiders own 2.20% of the company’s stock.
Several large investors have recently added to or reduced their stakes in HRC. Seven Eight Capital LP purchased a new stake in shares of Hill-Rom during the second quarter valued at approximately $127,000. Citigroup Inc. boosted its stake in shares of Hill-Rom by 21.1% during the second quarter. Citigroup Inc. now owns 2,483 shares of the medical technology company’s stock valued at $198,000 after purchasing an additional 433 shares during the period. DekaBank Deutsche Girozentrale boosted its stake in shares of Hill-Rom by 101.0% during the third quarter. DekaBank Deutsche Girozentrale now owns 2,720 shares of the medical technology company’s stock valued at $204,000 after purchasing an additional 1,367 shares during the period. Fox Run Management L.L.C. purchased a new stake in shares of Hill-Rom during the third quarter valued at approximately $207,000. Finally, CAPROCK Group Inc. purchased a new stake in shares of Hill-Rom during the fourth quarter valued at approximately $211,000. 81.92% of the stock is owned by hedge funds and other institutional investors.
WARNING: This piece of content was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this piece of content on another publication, it was illegally stolen and republished in violation of US & international trademark & copyright legislation. The original version of this piece of content can be viewed at https://www.thecerbatgem.com/2018/01/20/hill-rom-hrc-given-buy-rating-at-needham-company-llc.html.
Hill-Rom Company Profile
Hill-Rom Holdings, Inc is a global medical technology company. The Company operates through four segments: North America Patient Support Systems, International Patient Support Systems, Front Line Care and Surgical Solutions. The Company’s products and services include Patient Support Systems, Front Line Care and Surgical Solutions.
Receive News & Ratings for Hill-Rom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hill-Rom and related companies with MarketBeat.com's FREE daily email newsletter.